BioNTech SE (BNTX) Stock
BNTX has an Alpha Score of 15 out of 100 (poor), computed on Oct 30, 2026 from 2 of 4 sub-scores. 2 members of Congress disclosed 8 trades in BNTX since 2023: 4 purchases and 4 sales, most recently Valerie Hoyle (sale, Aug 7, 2025). 5 of the hedge funds AlphaScala tracks reported BNTX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $38.84M. Company insiders reported 0 open-market buys and 26 sales on SEC Form 4 in the 90 days to Nov 2, 2026.
What is BNTX's Alpha Score?
How it works →Alpha Score of 15 reflects poor overall profile with poor momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 30, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded BioNTech SE (BNTX)?
Most recent: Valerie Hoyle (sale, Aug 7, 2025); records start Dec 5, 2023.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Val Hoyle D-OR · House | 2025-08-07 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-09-03 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-08-30 | partial sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-04-15 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-03-14 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-12-07 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-12-06 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-12-05 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 1, 2026.
See all BNTX political trades →Which hedge funds own BNTX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 417K | $38.84M | +109% |
| Marshall Wace | 382K | $35.61M | +53% |
| Citadel Ken Griffin | 365K | $33.92M | -62% |
| Point72 Steve Cohen | 327K | $30.44M | NEW |
| ARK Invest Cathie Wood | 133K | $12.41M | +4% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are BioNTech SE insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 9, 26 | Sahin Ugur | Chief Executive Officer | SELL | 36.2K | $3.5M |
| Oct 8, 26 | Sahin Ugur | Chief Executive Officer | SELL | 27.0K | $2.5M |
| Oct 7, 26 | Sahin Ugur | Chief Executive Officer | SELL | 24.0K | $2.3M |
| Oct 6, 26 | Sahin Ugur | Chief Executive Officer | SELL | 21.0K | $2.0M |
| Oct 5, 26 | Sahin Ugur | Chief Executive Officer | SELL | 72.0K | $7.0M |
| Oct 2, 26 | Sahin Ugur | Chief Executive Officer | SELL | 17.0K | $1.6M |
| Oct 1, 26 | Sahin Ugur | Chief Executive Officer | SELL | 17.0K | $1.7M |
| Sep 30, 26 | Sahin Ugur | Chief Executive Officer | SELL | 32.0K | $3.1M |
| Sep 29, 26 | Sahin Ugur | Chief Executive Officer | SELL | 34.0K | $3.3M |
| Sep 28, 26 | Sahin Ugur | Chief Executive Officer | SELL | 34.0K | $3.3M |
SEC Form 4 filings as of Nov 2, 2026
See cluster-buy signals across all tickers →What are BNTX's key statistics?
Key statistics as of Oct 22, 2026
How does BNTX's valuation compare with the Healthcare sector?
| Metric | BNTX | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -63.64% | 4.85% | 143 |
| Return on equity | -9.10% | 6.68% | 162 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 3, 2026). P/E excludes loss-making companies.
BNTX price chart
Powered by TradingViewWhat does BioNTech SE do?
BioNTech SE is a German multinational biotechnology company headquartered in Mainz, specializing in the development of immunotherapies and vaccines for cancer and infectious diseases. Founded in 2008 by Uğur Şahin, Özlem Türeci, and Christoph Huber, it leverages advanced platforms like mRNA technology, next-generation immunomodulators, targeted therapies, and antibody-drug conjugates to address unmet medical needs. The company gained global prominence through its partnership with Pfizer to develop Comirnaty, the first approved mRNA-based COVID-19 vaccine, while advancing a diversified oncology pipeline with late-stage programs targeting various cancer stages, from early high-risk to metastatic diseases. BioNTech SE operates a global network of research, manufacturing, and commercial sites across Europe, North America, Asia, Australia, and Africa, including innovative BioNTainer systems for scalable mRNA production. Recent strategic moves, such as acquiring InstaDeep for AI-driven drug discovery, CureVac for enhanced mRNA capabilities, and Biotheus for advanced drug candidates, underscore its commitment to innovation. Employing over 6,000 professionals, BioNTech SE plays a pivotal role in transforming oncology and infectious disease treatments through synergistic multi-modal approaches and computational advancements.